Actinium Pharmaceuticals, Inc. (ATNM)

Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.

Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.

Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.

EPS growth above 1.5x AGEN's 8.93%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.

Diluted EPS growth above 1.5x AGEN's 8.93%. David Dodd would see if there's a robust moat protecting these shareholder gains.

Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.

Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.

Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.

Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.

3Y OCF/share CAGR above 1.5x AGEN's 19.94%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.

Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.

5Y net income/share CAGR above 1.5x AGEN's 46.94%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.

3Y net income/share CAGR above 1.5x AGEN's 12.18%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.

Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.

Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.

Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Asset growth above 1.5x AGEN's 3.18%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.

BV/share growth above 1.5x AGEN's 4.29%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

We’re deleveraging while AGEN stands at 26.73%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.

Our R&D shrinks while AGEN invests at 6.01%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.

We cut SG&A while AGEN invests at 33.75%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.